ClinicalTrials.gg
RecruitingNCT05587049ESVECOUpdated Aug 26, 2026

A Study to Assess Change in Disease State in Adult Participants With Acute Myeloid Leukemia (AML) Receiving Oral Venetoclax Tablets in Combination With Subcutaneously (SC) or Intravenously (IV) Injected Azacitidine in Colombia

An observational study in Acute Myeloid Leukemia, sponsored by AbbVie. Recruiting at 8 sites in Colombia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-26.

Sponsored by AbbVie · Observational

From the registry’s dates

  • Started Nov 2023; still recruiting 2 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
70
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 43 studies in Leukemia, Myeloid, Acute by AbbVie — 4 open to participants now, 10 under way, 3 of them phase 3. Leukemia, Myeloid, Acute · AbbVie.

Planned enrollment
8th of 10
70 · median 113
Started
2023
with 2 others
Observational
10 of 43
1 open now
Registered
36th of 43
by date

Among the 43 studies in Leukemia, Myeloid, Acute by AbbVie, this one is the 8th largest by planned enrollment of the 10 observational ones that give a count, is one of 3 that started in 2023, is one of 10 observational ones, and was the 36th registered.

Leukemia, Myeloid, Acute

3,669 studies on the registry are indexed under Leukemia, Myeloid, Acute; 813 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

4 of the 43 studies in Leukemia, Myeloid, Acute by AbbVie are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 621 Leukemia, Myeloid, Acute studies recruiting now, 361 (58%) set no upper age limit and 220 (35%) stop at 75 or younger; 145 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies in Leukemia, Myeloid, Acute by AbbVie, or all of them as a file.
02

Study summary

Acute myeloid leukemia (AML) is a cancer of the blood and bone marrow and is the most common acute leukemia in adults. This study will evaluate how well venetoclax in combination with azacitidine works to treat AML in adult participants in Colombia.

Venetoclax in combination with azacytidine is approved to treat Acute myeloid leukemia (AML). All study participants will receive venetoclax in combination with azacitidine as prescribed by their study doctor in accordance with approved local label. Adult participants with a new diagnosis of AML will be enrolled. Around 70 participants will be enrolled in the study in Colombia.

Participants will receive venetoclax tablets to be taken by mouth in combination with azacitidine given by subcutaneous (SC) or intravenous (IV) injection according to the approved local label. The duration of the study is approximately 36 months.

There is expected to be no additional burden for participants in this trial. All study visits will occur during routine clinical practice.

03

Conditions studied

  • Acute Myeloid Leukemia

Keywords

  • Acute Myeloid Leukemia
  • Venetoclax
  • Venclexta
  • Venclyxto
  • Azacitidine
  • ABT-199
  • Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Newly diagnosed AML participants who are ineligible to intensive chemotherapy, that starting treatment with Venetoclax in combination with azacytidine treated according to the Colombia label.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Newly diagnosed acute myeloid leukemia (AML) defined as participants that have histological confirmation of AML (de novo, secondary) by World Health Organization (WHO) criteria, and have not received any prior treatment for AML.
  • Ineligible to intensive chemotherapy due to >=75 years of age; or >=18 to 74 years who have comorbidities that preclude use of intensive induction chemotherapy.
  • Participants starting treatment with venetoclax in combination with azacytidine treated according to the Colombia label and who are not completed the first cycle (Cycle 28 days).

Exclusion criteria

Exclusion Criteria:

- Participating in an interventional clinical trial within 30 days prior to Venetoclax treatment initiation.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
70 participants (estimated)

Groups and cohorts

  • Venetoclax + Azacitidine Participants

    Participants treated with venetoclax in combination with azacitidine in accordance with approved local label.

06

What researchers measure

Primary outcomes

  1. Overall Survival (OS)

    OS defined as the time from the date of start Venetoclax to the date of death from any cause.

    Time frame: Up to 18 months

Secondary outcomes

  1. Percentage of Participants Achieving Complete Remission (CR)

    CR is defined according to the modified International Working Group (IWG) criteria for acute myeloid leukemia (AML) as no morphologic evidence of AML and absolute neutrophil count \>=10\^3 /μL (\>=1.0 x 10\^9 /L), platelets \>=10\^5 /μL (\>=100 x 10\^9 /L), red blood cell (RBC) transfusion independence, and bone marrow with \<5% blasts. Absence of circulating blasts and blasts with Auer rods; absence of extramedullary disease.

    Time frame: Up to 18 Months

  2. Percentage of Participants Achieving Complete Remission with Incomplete Marrow Recovery (Cri)

    Cri is defined according to the modified IWG criteria for AML as all criteria as CR except for residual neutropenia \<10\^3 /μL (1,000/ μL), or thrombocytopenia \<10\^5 /μL (100,000/ μL). If all criteria for CR are meet except for RBC transfusion independence, this also fulfills Cri criteria.

    Time frame: Up to 18 Months

  3. Percentage of Participants Achieving Complete Remission with Incomplete Marrow Recovery (CRh)

    CRh is defined according to the modified IWG criteria for AML as bone marrow with \< 5% blasts and Peripheral blood neutrophil count of \> 0.5 × 10\^3 /μL and Peripheral blood platelet count of \> 0.5 × 10\^5 /μL and 1-week (\>= 7 days) platelet transfusion-free period prior to the hematology lab collection.

    Time frame: Up to 18 Months

  4. Percentage of Participants Achieving Transfusion Independence

    Transfusion ndependence is defined as a period of at least 56 days with no transfusion between the first dose of Venetoclax and the last dose of Venetoclax plus 30 days.

    Time frame: Up to 18 Months

  5. Event-Free Survival (EFS)

    EFS defined as the time from the date of start Venetoclax to the date of morphologic relapse, progressive disease, resistant disease, treatment failure, or death from any cause.

    Time frame: Up to 18 Months

  6. Duration of Remission (DOR)

    DOR defined as the time from the date of first CR, CRi or CRh to the earliest evidence of morphologic relapse, progressive disease, or death due to disease progression.

    Time frame: Up to 18 Months

  7. Duration of Treatment (DoT)

    DoT defined as the time from the start of a therapy to the time of treatment discontinuation for any reason.

    Time frame: Up to 18 Months

  8. Percentage of participants with Adverse Events (AE)

    AE, defined as any unfavorable medical event that is temporarily related to the use of the investigational product, which does not necessarily have a causal relationship with the investigational product.

    Time frame: Up to 18 Months

  9. Percentage of participants achieving Minimal Residual Disease (MRD) negativity

    MRD negativity, defined as having less than 10\^-3 residual blasts per leukocyte measured in the bone marrow.

    Time frame: Up to 18 Months

  10. Change in Health-Related Quality of Life (HRQOL) Score

    HRQOL score, defined as a multidimensional construct defined as the subjective perception of the life as a whole, including physical, emotional, social, cognitive functions, disease symptoms and side effects of treatment.

    Time frame: Up to 18 Months

07

Study locations

2 of 8 sites recruiting
  • Hospital Pablo Tobon Uribe /ID# 248569
    Medellín, Antioquia 050034, Colombia
    Active, not recruiting

    Not enrolling at this site.

  • Hospital Alma Mater de Antioquia /ID# 248562
    Medellin, Bogota D.C. 50010, Colombia
    Active, not recruiting

    Not enrolling at this site.

  • Sociedad de Oncologia y Hematologia del Cesar /ID# 248615
    Valledupar, Cesar Department 200001, Colombia
    Completed

    Not enrolling at this site.

  • Coorp Hosp Juan Ciudad Sede Hospital Universitario Mayor Mederi /ID# 248570
    Bogota DC, Cundinamarca 111221, Colombia
    Active, not recruiting

    Not enrolling at this site.

  • Fundacion Santa Fe De Bogota /ID# 248563
    Bogota, Cundinamarca 110111, Colombia
    Recruiting
  • Clinica del Country /ID# 248430
    Bogota, Cundinamarca 110231, Colombia
    Recruiting
  • FOSCAL International /ID# 287252
    Floridablanca, Santander Department 681004, Colombia
    Active, not recruiting

    Not enrolling at this site.

  • Fundacion Valle Del Lili /ID# 248294
    Cali, Valle del Cauca Department 760016, Colombia
    Active, not recruiting

    Not enrolling at this site.

08

References and documents

Related links

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2023 (actual). Primary completion is estimated for Nov 2026, 36 months after the start.

Of 160 observational studies under Leukemia, Myeloid, Acute, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 154. This study's planned 36 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 18, 2022
First posted
Oct 19, 2022
StartActual
Nov 30, 2023
Primary completionEst.
Nov 2026
CompletionEst.
Nov 2026
Last update
Aug 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 26, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05587049
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Oct 19, 2022
Start date
Nov 30, 2023
Primary completion
Nov 2026 (estimated)
Completion
Nov 2026 (estimated)
Last update
Aug 26, 2026

Study contacts

Angela Duarte
Contact
angela.duarte@abbvie.com
+57 1 638-5000
ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion